美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Health Innovation Active ETF

34.17

+0.60801.81%

盤後：34.170.00000.00%16:10 EDT

成交量：176

成交額：6,029

市值：1,366.76萬

市盈率：- -

高：34.17

開：33.56

低：34.17

收：33.56

52周最高：34.86

52周最低：25.79

股本：40.00萬

流通股本：40.00萬

量比：0.31

換手率：0.04%

股息：0.08

股息率：0.23%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

中國生物製藥(01177.HK)：LM-364「NECTIN-4TMEADC」臨床試驗申請獲NMPA及FDA批准

ST百靈：「糖寧通絡片」獲中國澳門特別行政區藥監局Ⅲ期臨床試驗預先許可

金佰利·克拉克尋求歐盟批准這筆400億美元的Kenvue收購交易

美國食品藥品監督管理局（FDA）批准吉利德治療艾滋病的每日一次複方片劑

美國FDA批准吉利德科學Bixlenvo™上市：每日單片方案為病毒學抑制HIV成人患者提供新選擇，涵蓋複雜治療方案人群

宜明昂科-B(01541)：IMM2510聯合IMM27M一線治療晚期HCC的II期臨床試驗完成首例患者給藥

美國醫療保險和醫療補助服務中心：特朗普政府宣佈撥款9330萬美元，用於在佐治亞州擴展遠程醫療服務、推進手術機器人技術及改

石藥集團(01093)：高活性胰澱素受體激動劑(SYH2092注射液)在中國獲批開展臨床試驗

石藥創新：控股子公司SYH2092獲藥物臨床試驗批准通知書

中國批准強生公司口服銀屑病藥，該藥企表示

強生口服Icotrokinra在華獲批，用於治療中重度斑塊狀銀屑病

Globus Medical收購數字醫療企業完善外科智能佈局

強生公司8月27日宣佈，白介素23（IL-23）受體拮抗劑艾特雅（鹽酸伊可白滯素片）已正式獲得中國國家藥品監督管理局批准

強生靶向口服肽類藥物艾特雅在華獲批

港股異動 | 宜明昂科-B(01541)漲近12% 公司現金儲備保持充沛多項關鍵臨床試驗達重要節點

智通财经网

鼻病毒疫苗1期臨床試驗取得積極初步結果

麥科醫藥-B(02335)：MT200605用於急性缺血性腦卒中(AIS)的II期臨床試驗在中國完成

麥科醫藥-B(02335.HK)：MT200605用於急性缺血性腦卒中(AIS)的II期臨床試驗在中國完成

宜明昂科-B(01541)發布中期業績實現收入2542.4萬元多項關鍵臨床試驗達到重要節點

博安生物(06955)：BA2201(TL1A/IL-23)臨床試驗申請獲CDE受理

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BMED/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":34.1689,"timestamp":1789675200000,"preClose":33.5609,"halted":0,"volume":176,"hourTrading":{"tag":"盘后","latestPrice":34.1689,"preClose":34.1689,"latestTime":"16:10 EDT","volume":8,"amount":273.3512,"timestamp":1789675803872,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.018116319884151025,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"盤後交易","change":0.608,"latestTime":"09-17 16:28:19 EDT","open":33.5609,"high":34.1689,"low":34.1689,"amount":6029,"amplitude":0,"askPrice":50.97,"askSize":200,"bidPrice":16.99,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789689600000},"marketStatusCode":4,"adr":0,"exchange":"ARCA","adjPreClose":33.5609,"sharesOutstanding":360000,"nav":33.339378,"aum":13335751.2,"dividendRate":0.002333,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.1689,"preClose":34.1689,"latestTime":"16:10 EDT","volume":8,"amount":273.3512,"timestamp":1789675803872,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.305238,"impliedVol":0.0628,"impliedVolPercentile":0.004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.305238,"shares":400000,"dividePrice":0.0797,"high":34.1689,"amplitude":0,"preClose":33.5609,"low":34.1689,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":34.1689,"eps":0,"divideRate":0.002333,"volume":176,"delay":0,"ttmEps":0,"open":33.5609,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":32.8027,"twentyDayClose":34.7939,"sixtyDayClose":28.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662689280","title":"中國生物製藥(01177.HK)：LM-364「NECTIN-4TMEADC」臨床試驗申請獲NMPA及FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2662689280","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662689280?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 16:52","pubTimestamp":1787907146,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","LABU","BK4588","BK4585","IBBJ","IBBQ","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662050051","title":"ST百靈：「糖寧通絡片」獲中國澳門特別行政區藥監局Ⅲ期臨床試驗預先許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2662050051","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662050051?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 16:41","pubTimestamp":1787906506,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBQ","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662057892","title":"金佰利·克拉克尋求歐盟批准這筆400億美元的Kenvue收購交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2662057892","media":"路透中文","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662057892?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 15:49","pubTimestamp":1787903373,"startTime":"0","endTime":"0","summary":"金佰利·克拉克寻求欧盟批准这笔400亿美元的Kenvue收购交易路透8月28日-欧盟委员会网站上的文件显示，金佰利·克拉克KMB.O已向欧盟监管机构申请批准其拟以400亿美元 (link) 收购泰诺（Tylenol）制造商肯维（Kenvue）的交易。金佰利·克拉克于去年11月宣布了此次收购计划。该公司当时表示，该交易预计将于2026年下半年完成。金佰利·克拉克预计该交易将带来21亿美元的年度成本节约。该公司表示，通过收购肯维旗下从李施德林漱口水到艾维诺、露得清等护肤品牌的庞大产品组合，合并后公司预计将实现约320亿美元的年收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL4S44P0IB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PJP","IE00BDGV0183.EUR","LU0289739699.SGD","LU0882574055.USD","LU0640476718.USD","RSPS","KVUE","LU0058720904.USD","BMED","LU1585245621.USD","SG9999002232.USD","LU2347655156.SGD","LU1506573853.SGD","IHE","LU1280957306.USD","LU2129689431.USD","LU1061106388.HKD","LU0114720955.EUR","LU2430703095.HKD","LU2471134952.CNY","GLAM","JDOC","LU2456880835.USD","VHT","BK4568","LU1023059063.AUD","LU1732799900.SGD","LU2602419157.SGD","JNJ","LU2417539215.USD","LU0683600562.USD","IXJ","TRUH","FHLC","RXL","MEDX","GDOC","BK4585","LU0545562505.USD","IE00B42XCP33.USD","IYH","LU1043141123.HKD","XLV","LU2213496289.HKD","LU1244550494.USD","LU0795875086.SGD","BK4588","LU0320765646.SGD","KMB","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036374","title":"美國食品藥品監督管理局（FDA）批准吉利德治療艾滋病的每日一次複方片劑","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036374","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662036374?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 05:50","pubTimestamp":1787867453,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）批准吉利德治疗艾滋病的每日一次复方片剂路透8月27日-吉利德科学公司周四表示，美国食品和药物管理局已批准该公司研发的每日一次口服复方药GILD.O，用于治疗HIV病毒载量已降至极低水平的成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4S44O24V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBH","LU0965508806.USD","LU1674673691.USD","MEDI","LU1037948541.HKD","SG9999015986.USD","LU1066053197.SGD","IE0002270589.USD","LU1934455277.USD","BK4585","LU0114720955.EUR","LU2324357040.USD","IE00BZ1G4Q59.USD","TMED","LU0109394709.USD","LU2468319806.SGD","GILD","IBBQ","LU1571399168.USD","BMED","TBXU","BK4583","SG9999015952.SGD","LU0058720904.USD","BK4568","BK4139","SG9999015978.USD","LU0289739699.SGD","IBB","LU0823416689.USD","BK4532","IE00B19Z3581.USD","LU1934455194.USD","LU1430594728.SGD","IE00B3T34201.USD","BIB","BK4566","LU1839511570.USD","LU1061106388.HKD","SG9999015945.SGD","LU2112291526.USD","IE00BKVL7J92.USD","LU0965509101.SGD","LU1023059063.AUD","IE00B7SZLL34.SGD","LU1778281490.HKD","LU0861579265.USD","LU1037948897.HKD","LU0889565916.HKD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198194055","title":"美國FDA批准吉利德科學Bixlenvo™上市：每日單片方案為病毒學抑制HIV成人患者提供新選擇，涵蓋複雜治療方案人群","url":"https://stock-news.laohu8.com/highlight/detail?id=1198194055","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198194055?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 05:49","pubTimestamp":1787867358,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局正式批准了吉利德科学旗下新药Bixlenvo。这款每日一次的单片制剂，专为病毒学抑制状态的HIV成人感染者设计——即便是那些正在接受复杂治疗方案的病患，也适用这一新选项。此项获批标志着HIV治疗领域又添一枚重要砝码。Bixlenvo以单片复方形式呈现，将给药频率与用药负担同步压缩，患者无需再面对繁琐的多药组合。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0861579265.USD","LU0965509010.AUD","SG9999015978.USD","LU0882574055.USD","LU1037948897.HKD","LU1571399168.USD","BMED","LU0965509283.SGD","LU0058720904.USD","SG9999015952.SGD","LU1674673428.USD","LU0109394709.USD","LU0234570918.USD","LU1934455194.USD","LU0889565916.HKD","LU0320765992.SGD","LU0823416689.USD","LU1037948541.HKD","LU0122379950.USD","LU1674673691.USD","IE0002270589.USD","IE00BZ1G4Q59.USD","LU1778281490.HKD","IE00B19Z3581.USD","LU2324357040.USD","BK4578","IBBQ","LU1066051498.USD","LU0289739699.SGD","LU1066053197.SGD","BK4139","LU0965509101.SGD","LU1839511570.USD","BBH","IBB","TBXU","LU0965508806.USD","IE00BSNM7G36.USD","LU1061106388.HKD","LU2357627491.SGD","BK4532","LU1934455863.HKD","LU2112291526.USD","SG9999015945.SGD","IE00B7SZLL34.SGD","LU2087621335.USD","BK4583","BK4588","IE00B3T34201.USD","MEDI","BK4566","LU1585245621.USD","LU1934455277.USD","LU0114720955.EUR","LU1057294990.SGD","SG9999015986.USD","BIB","IE00BKVL7J92.USD","LU0859254822.USD","GILD","IE00B19Z3B42.SGD","LU1430594728.SGD","LU1023059063.AUD","BK4585","BK4550","LU2089984988.USD","LU2468319806.SGD","BK4568","TMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662008845","title":"宜明昂科-B(01541)：IMM2510聯合IMM27M一線治療晚期HCC的II期臨床試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2662008845","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662008845?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 21:21","pubTimestamp":1787836891,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM2510联 合 IMM27M一线治疗晚期肝细胞癌患者的II期临床试验顺利完成首例患者给药。该研究旨在评估IMM2510联合IMM27M在该患者群体中的初步疗效及安全性。自2023年首次提交IMM2510联合IMM27M的试验性新药申请以来，该联合疗法的临床开发稳步推进，并展现出卓越的潜力。令人鼓舞的早期临床结果证实，IMM2510联合IMM27M在晚期实体瘤治疗中具有显著的抗肿瘤活性及可控的安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","MDTX","HCC","BK1161","BMED","COAL","IBBJ","BK4006","IBBQ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662702216","title":"美國醫療保險和醫療補助服務中心：特朗普政府宣佈撥款9330萬美元，用於在佐治亞州擴展遠程醫療服務、推進手術機器人技術及改","url":"https://stock-news.laohu8.com/highlight/detail?id=2662702216","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662702216?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 20:14","pubTimestamp":1787832855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4154","LU0211331839.USD","LU0256863811.USD","LU0238689110.USD","LU1093756168.USD","LU1093756325.SGD","UNHW","IEIH","BK4585","LU0390134368.USD","LU0070302665.USD","LU0320765489.SGD","LU1983260115.SGD","RSPH","UNHU","HEAL","BK4588","BMED","BK4566","FXH","FDHT","SG9999014005.SGD","EKG","UN","MDEV","LU0266013472.USD","SG9999014013.SGD","LGHT","LU0208291251.USD","HUM","UNHG","BK4533","IHF","HTEC","LU0417517546.SGD","GDOC","LU0170899867.USD","LU0348723411.USD","SG9999014021.USD","IEHS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705535","title":"石藥集團(01093)：高活性胰澱素受體激動劑(SYH2092注射液)在中國獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705535","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662705535?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 18:26","pubTimestamp":1787826406,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的SYH2092注射液已获中国国家药品监督管理局批准，可在中国开展临床试验。该产品是一款胰淀素受体激动剂。临床前研究显示，与目前处于临床开发阶段的多个胰淀素类似物相比，该产品展现出更高的靶点激动活性、显着的减重效果及持久的减重维持作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1960683339.HKD","LU1008478684.HKD","LU1226287792.SGD","LU0140636845.USD","BK1191","MDTX","IBBQ","LU0501845795.SGD","LU1328277881.USD","LU2039709279.SGD","IE0008368742.USD","IE00BZ08YS42.EUR","LU1152091168.USD","LU0072913022.USD","LU1226287875.USD","IE00BZ08YR35.GBP","BMED","LU1813983027.USD","IE00B031HY20.USD","IE00BZ08YT58.USD","LU0067412154.USD","BK1521","LU1993786604.SGD","LU1807302812.USD","LU1226288253.USD","LU1951186391.HKD","PSYK","LU1226287529.USD","LU1152091754.HKD","IBBJ","BK1515","IE0008369823.USD","KURE","SG9999004220.SGD","LU0314109678.HKD","LU0326950275.SGD","HK0000165453.HKD","LU0880133367.SGD","IE00B543WZ88.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","01093","LU0315179316.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662772020","title":"石藥創新：控股子公司SYH2092獲藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2662772020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662772020?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 17:14","pubTimestamp":1787822087,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","IBBQ","PSYK","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774757","title":"中國批准強生公司口服銀屑病藥，該藥企表示","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774757","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662774757?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 16:54","pubTimestamp":1787820888,"startTime":"0","endTime":"0","summary":"中国批准强生公司口服银屑病药，该药企表示路透上海8月27日-强生公司（JNJ.N）周四表示，其口服药物伊科特罗金拉（icotrokinra）已在中国获批用于治疗中重度斑块型银屑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL4S44O0R7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHE","FTXH","FHLC","LU2456880835.USD","SG9999013999.USD","LU0124676726.USD","TRUH","JNJ","LU0345770308.USD","LU0882574055.USD","LU2487616109.SGD","JDOC","IYH","IE00BZ1G4Q59.USD","BK4588","VHT","LU2471134796.USD","LU1228905540.USD","RXL","IE00B2B36J28.USD","LU1221951046.USD","GDOC","LU2471134952.CNY","LU0640476718.USD","LU2602419157.SGD","SG9999001440.SGD","LU2430703178.SGD","MEDX","IXJ","LU0545562505.USD","IE00BGHQF631.EUR","SG9999001176.SGD","LU0345770993.USD","LU0053666078.USD","LU0162691827.USD","LU0345769631.USD","LU1983299246.USD","LU2023250330.USD","LU2089984988.USD","LU1244550494.USD","LU1074936037.SGD","LU0210536198.USD","LU1291159041.SGD","LU2236285917.USD","LU1032955483.USD","LU2896262040.SGD","PJP","LU1506573853.SGD","XLV","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113704178","title":"強生口服Icotrokinra在華獲批，用於治療中重度斑塊狀銀屑病","url":"https://stock-news.laohu8.com/highlight/detail?id=1113704178","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113704178?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 16:49","pubTimestamp":1787820549,"startTime":"0","endTime":"0","summary":"强生公司宣布，其口服药物Icotrokinra已获得中国监管部门的批准，用于治疗中重度斑块状银屑病。这一消息通过官方声明对外发布。\n该药物为患者提供了一种新的治疗选择，尤其针对那些患有中度至重度斑块状银屑病的成人群体。此次获批标志着强生在中国皮肤病治疗领域迈出了重要一步。\n值得注意的是，Icotrokinra作为一种口服疗法，相较于传统的注射或外用药物，可能为患者带来更多便利性和依从性。强生方面表示，将继续致力于为全球患者提供创新的医疗解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU0689472784.USD","BK4592","LU1121112475.USD","LU0345769128.USD","LU1061106388.HKD","LU2133065610.SGD","LU1043141123.HKD","LU2505996509.AUD","IE0002141913.USD","LU1674673691.USD","IE00BN8TJ469.HKD","LU1162221912.USD","VHT","RXL","IE000MB6IJN5.SGD","JNJ","LU1894683348.USD","LU0640476718.USD","LU1032955483.USD","LU2592432038.USD","IE00BZ1G4Q59.USD","LU0053666078.USD","IE00BFTCPJ56.SGD","LU0889566641.SGD","SG9999013999.USD","LU1261432733.SGD","LU1066051498.USD","BK4532","IE00BLSP4452.SGD","LU0162691827.USD","BK4007","IE00BDGV0183.EUR","IE00B2B36J28.USD","LU2089984988.USD","LU0426412945.USD","IXJ","LU2471134523.USD","IE0034235303.USD","LU0820561909.HKD","IE00B7SZLL34.SGD","IE00BJT1NW94.SGD","BK4559","LU0912757837.SGD","IE0001KFT4U8.USD","LU0289739699.SGD","IE00B4R5TH58.HKD","IE00B3PB1722.GBP","LU0683600562.USD","LU0689626769.HKD","LU1057294990.SGD","LU1778281490.HKD","LU2750360997.AUD","LU2471134879.HKD","LU1291159041.SGD","LU2756315318.SGD","TRUH","LU1228905540.USD","LU0985320562.USD","LU0994945656.USD","JDOC","LU2750360641.GBP","LU1066053197.SGD","LU1551013425.SGD","BK4504","IE000BZT7R73.USD","SG9999002232.USD","LU1496350502.SGD","LU0114720955.EUR","IE00BBT3K403.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","BK4568","FTXH","LU0795875169.SGD","LU1585245621.USD","LU1674673428.USD","LU0203347892.USD","LU1145028129.USD","IE00BLSP4239.USD","LU0345770993.USD","LU1244550494.USD","LU2417539215.USD","IE000WAW04H5.SGD","IE00B19Z3B42.SGD","LU0820561818.USD","LU1718418525.SGD","LU2112291526.USD","SG9999002224.SGD","IYH","LU2430703178.SGD","LU1032466523.USD","IE00BGHQF631.EUR","LU1929549753.HKD","LU1244550577.SGD","LU2023250330.USD","LU2129689431.USD","MEDX","LU1066051225.USD","LU1059921491.USD","LU1221951046.USD","XLV","IHE","LU0466842654.USD","LU1983299246.USD","LU2129689514.USD","LU2430703095.HKD","BMED","LU0122379950.USD","LU1221951129.SGD","BK4585","LU1989771016.USD","LU1430594728.SGD","PJP","LU1043141396.HKD","LU0545562505.USD","SG9999001176.USD","LU2129689605.HKD","LU0203345920.USD","LU0098860793.USD","LU2756315664.SGD","LU1244550221.USD","LU0124676726.USD","IE00BVYPNV92.GBP","LU0210536198.USD","LU0820562030.AUD","LU1894683264.USD","LU2213496289.HKD","IE00B42XCP33.USD","LU1732799900.SGD","LU1280957306.USD","LU1066051811.HKD","LU2602419157.SGD","LU2471134796.USD","LU0787776722.HKD","LU2487616109.SGD","LU0964807845.USD","LU0234572021.USD","LU0345770308.USD","LU0795875086.SGD","LU0426417589.USD","IE000F7OJYX1.SGD","GDOC","LU0210528500.USD","IE00B3T34201.USD","IE00BJJMRZ35.SGD","LU1506573853.SGD","LU1228905037.USD","BK4581","BK4588","LU0072461881.USD","LU1914381329.SGD","LU1629891620.HKD","LU0234570918.USD","LU1732800096.USD","LU0345769631.USD","IE0002270589.USD","BK4534","SGXZ80539844.SGD","LU1074936037.SGD","IE00B1BXHZ80.USD","LU2468319806.SGD","LU2896262040.SGD","LU0058720904.USD","LU0882574055.USD","IE00BSNM7G36.USD","IE000SO60NU8.SGD","LU1551013342.USD","LU2505996681.GBP","FHLC","LU1267930813.SGD","LU1196500208.SGD","IE000M9KFDE8.USD","IE0009355771.USD","SG9999001176.SGD","LU2430703251.USD","IE00BFXG1179.USD","BK4550","LU2456880835.USD","LU2471134952.CNY","BK4533","IE0000B7K699.USD","LU0320765646.SGD","IE00BVYPNW00.USD","LU0943347566.SGD","LU1935042991.SGD","LU2236285917.USD","LU2403377893.USD","SG9999001440.SGD","LU0070217475.USD","LU2347655156.SGD","LU0792757196.USD","IE00BKVL7J92.USD","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774138","title":"Globus Medical收購數字醫療企業 完善外科智能佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774138","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662774138?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 16:42","pubTimestamp":1787820165,"startTime":"0","endTime":"0","summary":"本次收购将Higgs Boson Health旗下软件开发团队与人工智能科研人才纳入Globus Medical，助力公司搭建覆盖完整诊疗环节的数字医疗生态体系。此次并购是Globus Medical从硬件器械向软硬件一体化方向延伸的重要动作。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305375","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","FDHT","HEAL","IEIH","IE0009354923.USD","FWD","GMED","FDIF","LGHT","GDOC","LU2065732104.USD","BMED","GINN","HTEC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774566","title":"強生公司8月27日宣佈，白介素23（IL-23）受體拮抗劑艾特雅（鹽酸伊可白滯素片）已正式獲得中國國家藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662774566?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 16:40","pubTimestamp":1787820043,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FTXH","FHLC","LU1551013342.USD","IYH","SG9999001176.SGD","IE00B4R5TH58.HKD","IE00BFXG1179.USD","BMED","LU2471134523.USD","IE0001KFT4U8.USD","LU0289739699.SGD","LU2417539215.USD","IE0002270589.USD","RXL","SGXZ80539844.SGD","LU1228905037.USD","BK4532","LU0683600562.USD","XLV","IE00B3T34201.USD","LU0820562030.AUD","LU0912757837.SGD","SG9999013999.USD","IE00BSNM7G36.USD","LU1506573853.SGD","BK4007","LU2112291526.USD","TRUH","LU0964807845.USD","BK4534","LU2505996509.AUD","IHE","LU2896262040.SGD","LU2403377893.USD","LU1074936037.SGD","LU1221951129.SGD","IXJ","GDOC","JNJ","LU1244550494.USD","LU0985320562.USD","LU2468319806.SGD","VHT","LU1228905540.USD","MEDX","LU0882574055.USD","JDOC","PJP","LU1261432733.SGD","LU1989771016.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662777108","title":"強生靶向口服肽類藥物艾特雅在華獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2662777108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662777108?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 16:33","pubTimestamp":1787819601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["JNJ","LU2750360997.AUD","LU0889566641.SGD","LU0994945656.USD","LU2403377893.USD","LU2430703095.HKD","RXL","VHT","LU2487616109.SGD","LU0689472784.USD","LU2430703178.SGD","LU1244550494.USD","PJP","FHLC","GDOC","LU0114720955.EUR","LU1043141396.HKD","LU2023250330.USD","LU0683600562.USD","LU1629891620.HKD","IE00BVYPNW00.USD","LU0070217475.USD","LU1023059063.AUD","LU1718418525.SGD","LU2129689514.USD","MEDX","BK4568","XLV","LU1221951046.USD","IE00BSNM7G36.USD","LU2756315664.SGD","BK4007","IE000M9KFDE8.USD","FTXH","IE00B1BXHZ80.USD","IXJ","LU0466842654.USD","IE000SO60NU8.SGD","LU2471134796.USD","IYH","LU1059921491.USD","BMED","BK4533","LU1430594728.SGD","IHE","LU2133065610.SGD","TRUH","IE000WAW04H5.SGD","JDOC","LU1496350502.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662672478","title":"港股異動 | 宜明昂科-B(01541)漲近12% 公司現金儲備保持充沛 多項關鍵臨床試驗達重要節點","url":"https://stock-news.laohu8.com/highlight/detail?id=2662672478","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662672478?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 10:49","pubTimestamp":1787798975,"startTime":"0","endTime":"0","summary":"宜明昂科-B(01541)大涨近12%，截至发稿，涨10.41%，报4.085港元，成交额342.9万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260827/20260827104951_52940.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260827/20260827104951_52940.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["PSYK","BK1161","BK4585","01541","BK4588","MDTX","IBBJ","IBBQ","BMED","KCAI","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662327724","title":"鼻病毒疫苗1期臨床試驗取得積極初步結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2662327724","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662327724?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 10:30","pubTimestamp":1787797807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["PSYK","IBBQ","IBBJ","BMED","MDTX","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662742710","title":"麥科醫藥-B(02335)：MT200605用於急性缺血性腦卒中(AIS)的II期臨床試驗在中國完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2662742710","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662742710?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 22:40","pubTimestamp":1787755220,"startTime":"0","endTime":"0","summary":"智通财经APP讯，麦科医药-B(02335)公布，集团自主研发的用于治疗急性缺血性脑卒中的候选药物MT200605的II期临床试验已完成。该临床试验已证明具有显著且稳健的疗效优势及良好的安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","IBBJ","AIS","02335","BK1161","MDTX","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662710777","title":"麥科醫藥-B(02335.HK)：MT200605用於急性缺血性腦卒中(AIS)的II期臨床試驗在中國完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2662710777","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662710777?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 22:40","pubTimestamp":1787755220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBQ","IBBJ","AIS","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662717577","title":"宜明昂科-B(01541)發布中期業績 實現收入2542.4萬元 多項關鍵臨床試驗達到重要節點","url":"https://stock-news.laohu8.com/highlight/detail?id=2662717577","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662717577?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 21:51","pubTimestamp":1787752295,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布截至2026年6月30日止6个月中期业绩，收入2542.4万元;研发开支1.55亿元，同比减少7.9%。公告称，收入截至2026年6月30日止6个月为人民币2542.4万元，主要归因于根据公司于2024年与Axion Bio, Inc.订立的授权及合作协议收取的付款。于报告期间，公司持续快速推进药物管线的开发，在肿瘤免疫治疗及自身免疫性疾病领域均取得重要里程碑及成就。IMM01、IMM0306 及IMM2510等主要临床阶段资产取得重大进展，多项关键临床试验达到重要节点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","MDTX","IBBQ","IBBJ","BMED","BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662713154","title":"博安生物(06955)：BA2201(TL1A/IL-23)臨床試驗申請獲CDE受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2662713154","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662713154?lang=zh_tw&edition=fundamental","pubTime":"2026-08-26 19:11","pubTimestamp":1787742677,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，BA2201的新药临床试验申请已获得中国国家药品监督管理局药品审评中心受理。BA2201有望成为中国首批进入临床阶段的TL1A/IL-23双抗药之一。针对上述临床需求，BA2201同时靶向IL-23和TL1A两条核心致病通路。临床前研究显示，BA2201可高效阻断TL1A与DR3的结合;其IL-23结合端亦保持较强的通路抑制活性。此外，BA2201高浓度皮下制剂具有良好稳定性，为临床给药提供便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082196.USD","MDTX","06955","IBBJ","BK1161","GDXJ","IBBQ","CDE","LU1223083913.SGD","SIL","XME","BK4017","LU1223082519.USD","PSYK","BMED","SGDM"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}